Search results for "MOTH"

showing 10 items of 2617 documents

Multidisciplinary system for detecting medication errors in antineoplastic chemotherapy.

2009

Objective. To analyze medication errors (MEs) in a multidisciplinary system with a Computerized Pharmacotherapy Process (CPP) in cancer patients. Design. A longitudinal, prospective 2-year (January 2003 —to December 2004) cohort study was made in adult patients administered antineoplastic treatment in Services of Oncology and Haematology. MEs were identified by double cross-validation of each stage of the pharmacotherapeutic process (prescription, preparation, dispensing, administration, and follow-up) carried out by the multidisciplinary team (physician, pharmacist, nurse) with CPP assistance. Variables. Number of MEs per 1000 patient-days, percentage according to the stage of the pharmac…

medicine.medical_specialtyMedication Systems Hospitalanimal structuresInterprofessional RelationsPharmacistNursesAntineoplastic AgentsPharmacistsCohort StudiesHospitals UniversityPharmacotherapyMultidisciplinary approachAntineoplastic chemotherapyPhysiciansmedicineHumansMedication ErrorsPharmacology (medical)Longitudinal StudiesProspective StudiesMedical prescriptionStage (cooking)Adult patientsbusiness.industrySurgeryOncologyEmergency medicinebusinessCohort studyFollow-Up StudiesJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
researchProduct

Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies: High-Dose Cyclophosphamide Versus Plerixafor. on Beha…

2016

Abstract Background. Peripheral blood stem cell (PBSC) collection prior to high dose chemotherapy for autologous transplantation (ASCT) is a standard of care, and an attractive alternative to the use of bone marrow cells, for transplantation in Multiple Myeloma (MM). The optimal methodology for mobilizing PBSC has yet to be defined, both G-CSF and GM-CSF can be used; although, the stimulatory effect may be more pronounced when given after high dose cyclophosphamide (usually administered at a dose of 1.5 to 6g/m2 IV for one to two days) and use of Plerixafor, a CXCR4 antagonist (Mozobil®). The latter 2 options are preferred, overall, in France. Indeed, it was shown that the most recent combi…

medicine.medical_specialtyMobilizationbusiness.industryPlerixaforImmunologyCell BiologyHematologymedicine.diseaseBiochemistrySurgeryTransplantationHigh dose chemotherapyHigh dose cyclophosphamidemedicineAutologous transplantationIntensive care medicinebusinessMultiple myelomaHematopoietic Stem Cell Mobilizationmedicine.drugBlood
researchProduct

Detection of periodontal pathogens in mothers of preterm birth and/or low weight

2019

Background The present study aims to estimate the possible relationship between periodontal pathogens in the oral cavity and the birth of Preterm Birth (PTB) and/or Low Birth Weight (LBW). Material and Methods It’s a case- control study with the subgengival biofilm samples were collected from four sites up deeper until 48 hours postpartum and were processes by Polymerase Chain Reaction (PCR) for presence the periodontal pathogens Prevotella intermedia (Pi), Fusobacterium nucleatum (Fn), Porphyromonas gingivalis (Pg), Treponema denticola (Td),  Tannerella forsythia (Tf) e Aggregatibacter actinomycetemcomitans (Aa). The mothers were divided into case grup (babies weighing < 2500g and/or gesta…

medicine.medical_specialtyMothersAggregatibacter actinomycetemcomitansPrevotella intermedia03 medical and health sciences0302 clinical medicinePregnancyMedicineTannerella forsythiaHumansPeriodontologyGeneral DentistryPeriodontitisbiologybusiness.industryObstetricsResearchAggregatibacter actinomycetemcomitansPrevotella intermediaInfant NewbornTreponema denticola030206 dentistry:CIENCIAS MÉDICAS [UNESCO]biology.organism_classificationmedicine.diseaseLow birth weightstomatognathic diseasesOtorhinolaryngologyPremature birthUNESCO::CIENCIAS MÉDICASPremature BirthSurgeryFemaleFusobacterium nucleatummedicine.symptombusinessPorphyromonas gingivalisTreponema denticola
researchProduct

1088 Minimally-invasive pelvic exenteration: a survival analysis

2021

Minimally-invasive pelvic exenteration: a survival analysis. Introduction/Background* Pelvic exenteration for recurrent and persistent gynecological malignancies is traditionally performed with open approach (OA). Nevertheless, reports on the use of minimally-invasive surgical (MIS) approach to pelvic exenteration have been published with promising results in terms of peri-operative morbidity. However, oncological safety of this approach has been poorly investigated. The aim of the present study was to assess the disease-free survival (DFS) and overall survival (OS) of patients undergoing minimally-invasive pelvic exenteration. Methodology All patients undergoing pelvic exenteration for gyn…

medicine.medical_specialtyMultivariate analysisSurgical approachPelvic exenterationbusiness.industryProportional hazards modelAdjuvant chemotherapymedicine.medical_treatmentSurgeryMedian follow-upMedicinebusinessGrading (tumors)Survival analysisMiscellaneous
researchProduct

Efficacy and Safety of Multiple Doses of Imab362 in Patients with Advanced Gastro-Esophageal Cancer: Results of a Phase Ii Study

2014

ABSTRACT Aim: IMAB362 is a monoclonal antibody specifically targeting claudin 18 isoform 2 (CLDN18.2), which is expressed on gastric cancer cells, whereas it is only present on a fraction of healthy stomach cells. This may reduce the risk of target-related side effects. Single-agent IMAB362 appears safe in patients with advanced gastro-esophageal cancer (GEC) based on data from a phase I trial. Methods: This international, multicenter, non-randomized phase IIa study (NCT01197885) investigated the efficacy and safety of repeated doses of IMAB362 (300 and 600 mg/m2) in patients with metastatic, refractory/recurrent, CLDN18.2-positive GEC (i.e. cancer of the stomach, the lower esophagus and th…

medicine.medical_specialtyNauseabusiness.industryPhases of clinical researchHematologyEsophageal cancermedicine.diseaseChemotherapy regimenGastroenterologyOncologyResponse Evaluation Criteria in Solid TumorsInternal medicineAnesthesiamedicineVomitingProgression-free survivalmedicine.symptomAdverse effectbusinessAnnals of Oncology
researchProduct

Efficacy, tolerability and influence on "quality of life" of nifedipine GITS versus amlodipine in elderly patients with mild-moderate hypertension.

2001

The main purpose of this study was to compare efficacy, tolerability and influence on quality of life (QOL) of nifedipine gastrointestinal therapeutic system (NI) 30-60 mg once a day vs amlodipine (AM) 5-10 mg once a day in elderly patients with mild-moderate hypertension.This was a randomized, double-blind, parallel-group, multicenter study. After a 2-week single-blind placebo run-in, patients were randomized to either NI 30 mg or AM 5 mg. Responders continued on the same dosage for 16 additional weeks, while non-responders were titrated to 60 mg NI or 10 mg AM.Blood pressure was measured by mercury sphygmomanometer and efficacy equivalence of NI and AM tested by covariance analysis. Diast…

medicine.medical_specialtyNifedipinemedicine.medical_treatmentBlood PressurePlaceboNifedipineQuality of lifeDouble-Blind MethodInternal MedicinemedicineHumansAmlodipineAgedAged 80 and overChemotherapybusiness.industryGeneral MedicineMiddle AgedCalcium Channel BlockersSurgeryNifedipine gitsBlood pressureTolerabilityTherapeutic EquivalencyAnesthesiaHypertensionQuality of LifeAmlodipineCardiology and Cardiovascular Medicinebusinessmedicine.drugBlood pressure
researchProduct

The use of normothermic machine perfusion to rescue liver allografts from expanded criteria donors

2021

The use of expanded criteria donors is one of the strategies used to overcome the gap between the demand for organs and the number of donors. Physicians debate the extent to which marginal grafts can be used. In recent years, normothermic machine perfusion (NMP) has been used to test liver viability before transplantation. Grafts underwent NMP whenever histological steatosis was &gt; 40% or there were at least three Eurotransplant criteria for expanded criteria donor (ECD). We used NMP to test 19 grafts, 3 from donation after type 3 controlled cardiac death (DCD), and 16 from donation after brain death (DBD). Only two grafts from DBD were not transplanted, because perfusion proved they were…

medicine.medical_specialtyNormothermic machine perfusionmedicine.medical_treatmentLiver transplantationExpanded Criteria DonormedicineOverall survivalHumansMachine perfusionLiver transplantationbusiness.industryGraft SurvivalOrgan Preservationmedicine.diseaseAllograftsTissue DonorsDonation after brain deathSurgeryTransplantationPerfusionGraft viabilitysurgical procedures operativeLiverExpanded criteria donors Graft viability Hypothermic machine perfusion Liver transplantation Normothermic machine perfusionSurgerySteatosisExpanded criteria donorsbusinessPerfusionHypothermic machine perfusion
researchProduct

Two consecutive clinical trials on cisplatin (CDDP), hepatic arterial infusion (HAI), and I.V. 5-fluorouracil (5-FU) chemotherapy for unresectable co…

1991

Several phase III clinical trials demonstrated that hepatic arterial chemotherapy for unresectable colorectal liver metastases is able to provide significantly higher response rates than those obtained by systemic route: in more than 500 patients collected from 6 randomized trials, the median values of objective response rates were 55% after fluoxuridine (FUdR) continuous hepatic arterial infusion (HAI) vs. 18.5% after FUdR or 5-fluorouracil (5-FU) intravenous (i.v.) chemotherapy. Furthermore, the majority of those studies reported that median survival increased in the patient subgroups treated with intrahepatic chemotherapy, even if not always statistically significant [1-6]. Certainly, FU…

medicine.medical_specialtyOrganoplatinum Compoundsmedicine.medical_treatmentPhases of clinical researchRectumGastroenterologyMetastasisHepatic arterial infusionInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansInfusions Intra-ArterialCisplatinChemotherapybusiness.industryLiver NeoplasmsGeneral MedicineMiddle Agedmedicine.diseaseSurgerySurvival RateClinical trialmedicine.anatomical_structureOncologyFluorouracilDrug EvaluationSurgeryFluorouracilColorectal NeoplasmsFloxuridinebusinessmedicine.drugJournal of Surgical Oncology
researchProduct

Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2010

Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up A. Okines, M. Verheij, W. Allum, D. Cunningham & A. Cervantes On behalf of the ESMO Guidelines Working Group* GI Clinical Trials Unit, Royal Marsden Hospital, Sutton, UK; Department of Radiation Oncology and Division of Cellular Biochemistry, The Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Department of Surgery, Royal Marsden Hospital, London; Department of Medicine, Royal Marsden Hospital, Sutton, UK; Department of Hematology and Medical Oncology, INCLIVA, University of Valencia, Valencia, Spain

medicine.medical_specialtyPalliative careTreatment outcomeMeta-Analysis as TopicStomach NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsGastroscopyRadiation oncologyEpidemiologymedicineHumansNeoplasm MetastasisNeoplasm StagingRandomized Controlled Trials as TopicRadiotherapybusiness.industryIncidenceGeneral surgeryPalliative CareCancerHematologymedicine.diseaseCombined Modality TherapySurvival AnalysishumanitiesSurgeryEuropeClinical PracticeTreatment OutcomeOncologyClinical trials unitDiagnosis treatmentChemotherapy AdjuvantbusinessFollow-Up StudiesAnnals of Oncology
researchProduct

Major autohemotherapy as a treatment modality for alveolar osteitis

2018

Purpose.&#x0D; Alveolar osteitis is the most common post-odontectomy complication. Although blood clot disintegration is known to be the cause of the condition, an agreement is lacking regarding a treatment of choice. The aim of the current study therefore was to evaluate major autohemotherapy as one treatment method.&#x0D; &#x0D; Patients and Methods.&#x0D; A total of 183 patients were categorized into 4 groups (I, II, III, and IV) according to pain severity (mild, moderate, severe, or agonizing, respectively). Major autohemotherapy was performed for all patients by withdrawing 225mL of patient's blood and mixing them with 225mL of Oxygen-Ozone gas (where Ozone concentration was 50µg/mL ga…

medicine.medical_specialtyPalliative treatmentbusiness.industryTreatment methodmedicine.disease:CIENCIAS MÉDICAS [UNESCO]SurgeryAutohemotherapyTreatment modalityCurative treatmentPain severityUNESCO::CIENCIAS MÉDICASMedicineOsteitisbusinessComplication
researchProduct